The call for RA stories received a fantastic response from the public and the reading panel had a tough job in selecting the contributions which would feature in the published volume. Once the successful contributions were chosen, Arthritis Ireland proceeded to design a book, which could be sold in the book trade and online.

**Results:** In September 2019, Arthritis Ireland published *My RA Story*: Personal accounts of living with rheumatoid arthritis. Launched in the National Library of Ireland by Sinead Moriarty, the 46 contributions touched upon themes of pain, fatigue, emotional impact, disability, surgery, education, career, family, goal-setting, self-management, connecting with others, hope, etc. The contributors came from people who were living with RA for over 40 years, as well as from those who were more recently diagnosed. The book is a hugely valuable contribution to health literature. Arthritis Ireland now plans to make the book available for sale internationally, through Amazon and other retail channels, as well as promoting it more extensively in rheumatology clinics.

In October, one of the contributors was interviewed on national television about her RA story, as part of a feature on World Arthritis Day.

**Conclusion:** This campaign gave people living with RA a platform to write about and share about their condition. Fronted by an RA champion with significant name recognition and an enormous audience in her own right, best-selling author, Sinead Moriarty, the book, *My RA Story*. Crucially, the book is a valuable resource for people who are newly diagnosed with the disease and uncertain of what the future holds.

**Acknowledgments:** This project was supported by an educational grant from MSD.

**Disclosure of Interests:** Brian Lynch Grant/research support from: Arthritis Ireland received a grant from MSD to develop this patient education programme. Brian Lynch has not benefited personally in any way.

DOI: 10.1136/annrheumdis-2020-eular.6466

---

**Table 1 – Results of the surveys, across different countries, concerning patient perspective on the efficacy and risks of glucocorticoids in patients with RA.**

<table>
<thead>
<tr>
<th>Country</th>
<th>Percentage of patients considering GCs as useful</th>
<th>Percentage of patients reporting some form of adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>2/3</td>
<td>1/3</td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** Tânia Santiago: None declared, Marieke Voshaar Grant/research support from: part of phd research, Speakers bureau: conducting a workshop (Pfizer), Maarten de Wit Grant/research support from: Dr. de Wit reports personal fees from Ely Lilly, 2019, personal fees from Celgene, 2019, personal fees from Pfizer, 2019, personal fees from Janssen-Cilag, 2017, outside the submitted work. Consultant of: Dr. de Wit reports personal fees from Ely Lilly, 2019, personal fees from Celgene, 2019, personal fees from Pfizer, 2019, personal fees from Janssen-Cilag, 2017, outside the submitted work., Speakers bureau: Dr. de Wit reports personal fees from Ely Lilly, 2019, personal fees from Celgene, 2019, personal fees from Pfizer, 2019, personal fees from Janssen-Cilag, 2017, outside the submitted work., Pedro Carvalho: None declared, Frank Buttgeriet Grant/research support from: Amgen, BMS, Celgene, GSK, Hexal, Horizon, Lilly, medac, Mundipharma, Novartis, Pfizer, Roche, and Sanofi., Maurizio Cutolo Grant/research support from: Bristol-Myers Squibb, Ailsa Bosworth Grant/research support from: Bristol-Myers Squibb, Actelion, Celgene, Consultant of: Bristol-Myers Squibb, Speakers bureau: Sigma-Alpha, Maarten Boers: None declared, José Antonio P. da Silva Grant/research support from: Pfizer, Abbvie, Consultant of: Pfizer, Abbvie, Roche, Lilly, Novartis

DOI: 10.1136/annrheumdis-2020-eular.3164